Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

(Neutral)

Rhea-AI Summary

Annexon (Nasdaq: ANNX) reported equity inducement grants to three new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The awards were approved on August 10, 2026.

In total, the new hires received options to purchase 287,500 shares of Annexon common stock. According to Annexon, the stock options have a 10-year term and an exercise price of $5.29 per share, equal to the closing price on August 14, 2026, the grant date. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.

Market Context

Recent insider data showed Net Buying, with 613,497 shares bought and 0 sold over 90 days. That owne...

Analysis

Recent insider data showed Net Buying, with 613,497 shares bought and 0 sold over 90 days. That ownership context accompanies the employee awards; investors can watch future vesting and share-count disclosures.

Key Figures

Employees receiving grants: 3 employees Shares under option: 287,500 shares Exercise price: $5.29 per share +4 more

7 metrics

Employees receiving grants 3 employees 2022 Employment Inducement Award Plan

Shares under option 287,500 shares Aggregate employee inducement grants

Exercise price $5.29 per share Equal to August 14, 2026 closing price

Option term 10 years Employee stock options

Vesting period 4 years Subject to continued employee service

First-year vesting 25% Shares underlying options vesting on first anniversary

Monthly vesting 1/48th Additional shares vesting monthly thereafter

Historical Context

5 past events · Latest: Aug 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 12	Second-quarter earnings	Neutral	+0.0%	Reported quarterly results, pipeline milestones, financing updates, and cash runway expectations.
Aug 12	Phase 3 trial update	Positive	+0.0%	Added Month 24 endpoint and launched an open-label extension for ARCHER II.
Aug 10	Board appointment	Positive	-1.0%	Appointed Mark Blumenkranz and announced Muneer Satter's board departure.
Aug 6	Clinical study update	Positive	+4.3%	Reported rapid strength improvements among the first ten FORWARD study patients.
Jul 30	Credit facility	Positive	-3.3%	Secured up to $200 million from Oxford Finance and drew $50 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Reactions were mixed: the clinical update rose 4.28%, board and financing announcements fell 1.02% and 3.32%, while two events recorded 0%.

Key Terms

inducement grants, nasdaq listing rule 5635(c)(4)

2 terms

inducement grants financial

"has granted inducement to three new non-executive employees"

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/17/2026 - 04:05 PM

BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $5.29, which was the closing price of Annexon’s common stock on August 14, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

What inducement grants did Annexon (ANNX) announce on August 17, 2026?

Annexon announced stock option inducement grants to three new non-executive employees. According to Annexon, these options cover a total of 287,500 shares of common stock and are granted under the 2022 Employment Inducement Award Plan in line with Nasdaq Listing Rule 5635(c)(4).

How many Annexon (ANNX) shares are covered by the new employee stock options?

The new inducement stock options cover 287,500 Annexon common shares in total. According to Annexon, these options were granted to three non-executive employees as part of their hiring packages under the company’s 2022 Employment Inducement Award Plan, subject to standard vesting conditions.

What is the exercise price and term of the new Annexon (ANNX) inducement options?

The inducement options have a ten-year term and an exercise price of $5.29 per share. According to Annexon, $5.29 was the closing price of its common stock on August 14, 2026, which is the official grant date for these stock options.

How do the new Annexon (ANNX) inducement options vest for the three employees?

The options vest over four years, with 25% vesting on the first anniversary of the grant date. According to Annexon, the remaining 75% of the shares vest in equal monthly installments over the next three years, contingent on each employee’s continued service.

Under which plan and Nasdaq rule were Annexon (ANNX) inducement grants issued?

The inducement grants were issued under Annexon’s 2022 Employment Inducement Award Plan. According to Annexon, the options were approved on August 10, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4), which governs equity grants as employment inducements.